Search Results

There are 3546 results for: content related to: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER)

  1. You have full text access to this OnlineOpen article
    Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome

    Annals of the New York Academy of Sciences

    Volume 1329, Issue 1, November 2014, Pages: 45–66, Arturo Benitez, Heather Edens, Jesse Fishman, Kimberly Moran and Mahnaz Asgharnejad

    Article first published online : 21 AUG 2014, DOI: 10.1111/nyas.12508

  2. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 30, Issue S1, June 2015, Pages: S1–S567,

    Article first published online : 12 JUN 2015, DOI: 10.1002/mds.26295

  3. Rotigotine transdermal patch for the treatment of Parkinson’s Disease

    Fundamental & Clinical Pharmacology

    Volume 27, Issue 1, February 2013, Pages: 81–95, Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti and Olivier Rascol

    Article first published online : 9 FEB 2012, DOI: 10.1111/j.1472-8206.2012.01028.x

  4. Transdermal Rotigotine: A Clinically Innovative Dopamine-Receptor Agonist for the Management of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 29, Issue 12, December 2009, Pages: 1452–1467, Dr. Jack J. Chen, Dr. David M. Swope, Dr. Khashayar Dashtipour and Dr. Kelly E. Lyons

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.29.12.1452

  5. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Article first published online : 19 JUN 2012, DOI: 10.1002/mds.25051

  6. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Article first published online : 28 MAY 2008, DOI: 10.1002/mds.22133

  7. Lack of Pharmacokinetic Interactions Between Transdermal Rotigotine and Oral Levodopa/Carbidopa

    The Journal of Clinical Pharmacology

    Volume 49, Issue 9, September 2009, Pages: 1047–1055, Marina Braun, Willi Cawello, Jens-Otto Andreas, Dipl Math, Hilmar Boekens and Rolf Horstmann

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009338481

  8. You have free access to this content
    Abstracts of The Movement Disorder Society's Eleventh International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 22, Issue S16, 2007, Pages: S1–S325,

    Article first published online : 24 APR 2007, DOI: 10.1002/mds.21535

  9. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Article first published online : 6 JUN 2014, DOI: 10.1002/mds.25914

  10. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors

    British Journal of Pharmacology

    Volume 172, Issue 4, February 2015, Pages: 1124–1135, Martyn Wood, Vanessa Dubois, Dieter Scheller and Michel Gillard

    Article first published online : 13 JAN 2015, DOI: 10.1111/bph.12988

  11. You have free access to this content
    POSTER SESSION 1, SUNDAY 24 AUGUST

    European Journal of Neurology

    Volume 15, Issue s3, August 2008, Pages: 32–220,

    Article first published online : 12 AUG 2008, DOI: 10.1111/j.1468-1331.2008.02285.x

  12. Thorough QT/QTc Study in Patients With Advanced Parkinson's Disease: Cardiac Safety of Rotigotine

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 5, November 2008, Pages: 595–603, M Malik, J-O Andreas, K Hnatkova, J Hoeckendorff, W Cawello, M Middle, R Horstmann and M Braun

    Article first published online : 23 JUL 2008, DOI: 10.1038/clpt.2008.143

  13. You have full text access to this OnlineOpen article
    Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit

    Movement Disorders

    Volume 28, Issue 12, October 2013, Pages: 1675–1682, Karen L. Eskow Jaunarajs, David G. Standaert, Tacey X. Viegas, Michael D. Bentley, Zhihao Fang, Bekir Dizman, Kunsang Yoon, Rebecca Weimer, Paula Ravenscroft, Tom H. Johnston, Michael P. Hill, Jonathan M. Brotchie and Randall W. Moreadith

    Article first published online : 3 SEP 2013, DOI: 10.1002/mds.25625

  14. Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole

    Movement Disorders

    Volume 22, Issue 16, 15 December 2007, Pages: 2398–2404, Nir Giladi, Babak Boroojerdi, Amos D. Korczyn, David J. Burn, Carl E. Clarke and Anthony H.V. Schapira

    Article first published online : 12 OCT 2007, DOI: 10.1002/mds.21741

  15. Rotigotine improves restless legs syndrome: A 6-month randomized, double-blind, placebo-controlled trial in the United States

    Movement Disorders

    Volume 25, Issue 11, 15 August 2010, Pages: 1675–1683, Wayne A. Hening, Richard P. Allen, William G. Ondo, Arthur S. Walters, John W. Winkelman, Philip Becker, Richard Bogan, June M. Fry, David B. Kudrow, Kurt W. Lesh, Andreas Fichtner and Erwin Schollmayer

    Article first published online : 13 JUL 2010, DOI: 10.1002/mds.23157

  16. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial

    European Journal of Neurology

    A. Antonini, L. Bauer, E. Dohin, W. H. Oertel, O. Rascol, H. Reichmann, M. Schmid, P. Singh, E. Tolosa and K. Ray Chaudhuri

    Article first published online : 22 JUN 2015, DOI: 10.1111/ene.12757

  17. You have free access to this content
    Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive

    British Journal of Clinical Pharmacology

    Volume 68, Issue 3, September 2009, Pages: 386–394, Marina Braun, Jan-Peer Elshoff, Jens-Otto Andreas, Louise Ischen Müller and Rolf Horstmann

    Article first published online : 26 MAY 2009, DOI: 10.1111/j.1365-2125.2009.03468.x

  18. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine

    Clinical Pharmacology in Drug Development

    Volume 3, Issue 3, May/June 2014, Pages: 187–193, Jan-Peer Elshoff, Willi Cawello, Jens-Otto Andreas and Marina Braun

    Article first published online : 12 FEB 2014, DOI: 10.1002/cpdd.78

  19. You have free access to this content
    Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function

    British Journal of Clinical Pharmacology

    Volume 73, Issue 1, January 2012, Pages: 46–54, Willi Cawello, Sascha Ahrweiler, Wladyslaw Sulowicz, Agnieszka Szymczakiewicz-Multanowska and Marina Braun

    Article first published online : 8 DEC 2011, DOI: 10.1111/j.1365-2125.2011.04053.x

  20. You have free access to this content
    Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine

    British Journal of Clinical Pharmacology

    Volume 67, Issue 2, February 2009, Pages: 209–215, Marina Braun, Willi Cawello, Hilmar Boekens and Rolf Horstmann

    Article first published online : 23 OCT 2008, DOI: 10.1111/j.1365-2125.2008.03334.x